Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment

被引：1
|
作者：
Sim, S. H.
Park, I. H.
Jung, K. H.
Kim, S-B
Ahn, J-H
Lee, K-H
Im, S-A
Im, Y-H
Park, Y. H.
Sohn, J. H.
Kim, Y. J.
Lee, S.
Kim, H-J
Chae, Y. S.
Park, K-H
Nam, B-H
Lee, K. S.
Ro, J.
机构：
[1] Natl Canc Ctr, Goyang, South Korea
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[6] Korea Univ, Seoul, South Korea
[7] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea
[8] Seoul Natl Univ, Bundang Hosp, Bundang, South Korea
[9] Chung Ang Univ, Coll Med, Seoul, South Korea
[10] Dong A Univ, Coll Med, Busan, South Korea
[11] Kyungpook Natl Univ, Coll Med, Daegu, South Korea
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-17-23
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-17-23
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
    Yuan, Ye
    Liu, Xumei
    Cai, Yi
    Li, Wenyuan
    SYSTEMATIC REVIEWS, 2022, 11 (01)
  • [22] Phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
    Barr, J. A.
    Sharma, P.
    Fabian, C. J.
    Yeh, H.
    Baccaray, S.
    Springer, M.
    Khan, Q. J.
    CANCER RESEARCH, 2016, 76
  • [23] A phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
    Rooney, Anthony
    Sharma, Priyanka
    O'Dea, Anne P.
    Nye, Lauren
    Elia, Manana
    He, Jianghua
    Fabian, Carol
    Khan, Qamar
    CANCER RESEARCH, 2022, 82 (04)
  • [24] Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
    Ma, Fei
    Ouyang, Quchang
    Li, Wei
    Jiang, Zefei
    Tong, Zhongsheng
    Liu, Yunjiang
    Li, Huiping
    Yu, Shiying
    Feng, Jifeng
    Wang, Shusen
    Hu, Xichun
    Zou, Jianjun
    Zhu, Xiaoyu
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (29) : 2610 - +
  • [25] Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
    Chew, Helen Kent
    Schwartzberg, Lee
    Badarinath, Suprith
    Rubin, Peter
    Shumaker, Grace
    Daugherty, James
    DeSilvio, Michelle
    Mahoney, Janine
    SPRINGERPLUS, 2014, 3
  • [26] Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
    Lin, Nancy U.
    Eierman, Wolfgang
    Greil, Richard
    Campone, Mario
    Kaufman, Bella
    Steplewski, Klaudia
    Lane, Stephen R.
    Zembryki, Denise
    Rubin, Stephen D.
    Winer, Eric P.
    JOURNAL OF NEURO-ONCOLOGY, 2011, 105 (03) : 613 - 620
  • [27] Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
    Nancy U. Lin
    Wolfgang Eierman
    Richard Greil
    Mario Campone
    Bella Kaufman
    Klaudia Steplewski
    Stephen R. Lane
    Denise Zembryki
    Stephen D. Rubin
    Eric P. Winer
    Journal of Neuro-Oncology, 2011, 105 : 613 - 620
  • [28] A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)
    Gomez, H.
    Neciosup, S.
    Tosello, C.
    Mano, M.
    Bines, J.
    Ismael, G.
    Santi, P. X.
    Pinczowsky, H.
    Neron, Y.
    Fanelli, M.
    Fein, L.
    Sampaio, C.
    Lerzo, G.
    Capo, A.
    Zarba, J. J.
    Blajman, C.
    Varela, M. S.
    Martinez-Mesa, J.
    Werutsky, G.
    Barrios, C. H.
    CANCER RESEARCH, 2013, 73
  • [29] A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
    Massimo Cristofanilli
    Stephen R. D. Johnston
    Alexey Manikhas
    Henry L. Gomez
    Oleg Gladkov
    Zhimin Shao
    Sufia Safina
    Kimberly L. Blackwell
    Ricardo H. Alvarez
    Stephen D. Rubin
    Sulabha Ranganathan
    Suman Redhu
    Maureen E. Trudeau
    Breast Cancer Research and Treatment, 2013, 137 : 471 - 482
  • [30] Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer.
    Guarneri, V.
    Frassoldati, A.
    Ficarra, G.
    Maiorana, A.
    Bettelli, S.
    Bottini, A.
    Cagossi, K.
    Bisagni, G.
    Ravaioli, A.
    Amadori, D.
    Musolino, A.
    Cavanna, L.
    Orlando, L.
    Giardina, G.
    Piacentini, F.
    Bagnalasta, M.
    Conte, P.
    CANCER RESEARCH, 2011, 71
12345